Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 20/20 | 1.00 |
| ▸ | PSEN2 | P49810 | 20/20 | 1.00 |
| ▸ | APH1B | Q8WW43 | 20/20 | 1.00 |
| ▸ | NCSTN | Q92542 | 20/20 | 1.00 |
| ▸ | APH1A | Q96BI3 | 20/20 | 1.00 |
| ▸ | PSENEN | Q9NZ42 | 20/20 | 1.00 |
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12525071 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL20495533 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL29358197 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL33171 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL30957093 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL29666504 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL23855805 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5620296 | 0.92 | PSEN1 (0.85) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4419147 | 0.89 | PSEN1 (0.80) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3046688 | 0.84 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220184109-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ABERRANT ANGIOGENESIS | MASSACHUSETTS EYE AND EAR INFIRMARY | 2022-06-16 | — | — | US | disclosed |
| US-10954490-B2 | Compositions and methods for epithelial stem cell expansion and culture | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20190017015-A1 | Compositions And Methods For Epithelial Stem Cell Expansion And Culture | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2019-01-17 | — | — | US | disclosed |
| US-20090209473-A1 | Componds and methods for pormoting angiogenesis | BIOINVENT INTERNATIONAL AB (SE) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220184109-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ABERRANT ANGIOGENESIS | VEGFA, PGF, FLT4 | PSEN1 1627/4885PSEN2 1043/4885APH1B 1948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.